Master Alliance Provisions Guide (MAPGuide)

NIH – MPP (C-TAP), COVID-19 Technologies, Patent and Biological Material License Agreement

  • Liability | Indemnification & liability

4. Sublicensing

4.2 The Licensee agrees that any sublicenses granted by it shall provide that the obligations to the IC of Paragraphs 5.1, 5.2, 8.1, 10.1, 10.2, 12.6, and 13.7–13.9 of this Agreement shall be binding upon the sublicensee as if it were a party to this Agreement. The Licensee further agrees to attach copies of these paragraphs to all sublicense agreements.

12. Negation Of Warranties And Indemnification

12.6 The Licensee shall indemnify and hold IC, its employees, students, fellows, agents, and consultants harmless from and against all liability, demands, damages, expenses, and losses, including but not limited to death, personal injury, illness, or property damage in connection with or arising out of:

(a) the use by or on behalf of the Licensee and its Sublicensees, its directors, employees, or third parties of any Licensed Patent Rights or Licensed Materials; or

(b) the design, manufacture, distribution, or use of any Licensed Products, Licensed Processes, or materials by the Licensee and its Sublicensee(s), or other products or processes developed in connection with or arising out of the Licensed Patent Rights or Licensed Materials